What concept sector does Yong Technology belong to? Analysis of Yongtai Technology Concept Segment; 1. Lithium battery: Mainly engaged in pharmaceutical intermediate business; In September 2017, the new phase of Yonggao Ceramics subsidiary's "3,000 tons annual output of lithium hexafluorophosphate project" was put into production and has begun shipping to major domestic and foreign customers. 2. Children's Medical: In April 2016, it was announced that the company planned to purchase 100% of the equity of Zhejiang Palm with a fixed cash increase, with a total price of 700 million yuan to purchase 90% of the equity of Foshan Palm. In addition, the company plans to increase supporting funds raised by 700 million yuan. The above-mentioned fixed issuance price and floor price are both 19.57 yuan/share. Zhejiang Palm's specialty API products, methyldopa and gabapentin, rank first in the country in terms of output; Foshan Palm's products cover digestive system drugs, antibiotics, cardiovascular drugs, children's drugs and other fields. Last year, Zhejiang Palm achieved a net profit of 36.18 million yuan, while Foshan Palm also turned a profit, with a net profit of 21.45 million yuan. 3. Fluorite: The company is the leading enterprise of fluorobenzene series fine chemicals with the most complete product chain and the largest production capacity in the industry. The fine chemicals sub-industry is at the high end of the fluorochemical industry and is the sub-industry with the highest added value and the largest product sales in the entire fluorochemical industry. 4. Organic light-emitting diodes: The company's CF photoresist products can be used in the production and manufacturing of organic light-emitting diode products, breaking overseas monopoly. A construction project with an annual output of 60 tons of organic light-emitting diode electronic materials is under construction. 5. Asthma: The company holds 15% of the equity of Shanghai Absen Pharmaceutical Co., Ltd. Recently, the montelukast sodium chewable tablets and ordinary tablets applied by Ambisin were approved by the State Food and Drug Administration, becoming the first generic product approved by the National Medical Products Administration. Pharmaceutical consistency evaluation of similar drugs. Therefore, Anbixin became the first drug research and development institution in China to hold a drug marketing license. Montelukast sodium is a leukotriene receptor antagonist used for the treatment and prevention of asthma in children and adults and for the treatment of allergic rhinitis. 6. Traditional Chinese Medicine: On April 20, 2020, the company stated on the interactive platform: Yongtai Palm has an annual output of 4,340 tons of raw materials and 600 million pills of traditional Chinese medicine. The first phase of the project is currently undergoing equipment installation and commissioning. 7. Generic drug consistency evaluation: Montelukast sodium chewable tablets and ordinary tablets applied by the joint-stock company Shanghai Absen were approved by the State Food and Drug Administration, becoming the first similar drugs to pass the generic drug consistency evaluation. Therefore, Shanghai Absen became the first drug research and development institution in the country to have a drug marketing license. 8. S&P Dow Jones A-shares: On December 1, 2018, the index compilation company S&P Dow Jones announced that it would include some Chinese A-shares in its global index system, basically classifying them as emerging markets. In September 2019, the S&P Dow Jones Emerging Markets Index was included in A-shares, with an inclusion factor of 25%. 9. Organic light-emitting diode materials: The company's CF photoresist products can be used in the production and manufacturing of organic light-emitting diode products to break overseas monopolies. A construction project with an annual output of 60 tons of organic light-emitting diode electronic materials is under construction. 10. Biomedicine: In April 2016, it was announced that the company planned to purchase 100% of the equity of Zhejiang Palm and 90% of the equity of Foshan Palm with a fixed increase in cash for a total price of 700 million yuan. In addition, the company plans to increase supporting funds raised by 700 million yuan. The above-mentioned fixed issuance price and floor price are both 19.57 yuan/share. Zhejiang Palm's specialty API products, methyldopa and gabapentin, rank first in the country in terms of output; Foshan Palm's products cover digestive system drugs, antibiotics, cardiovascular drugs, children's drugs and other fields. Last year, Zhejiang Palm achieved a net profit of 36.18 million yuan, while Foshan Palm also turned a profit, with a net profit of 21.45 million yuan. 11. New material concept: The company is one of the domestic manufacturers of fluorine fine chemicals with the most complete product chain and the largest production capacity. The fluorine fine chemicals industry we are engaged in is located at the top of the fluorine chemical industry chain, with high added value and a wide range of applications, including liquid crystal materials, medicines, pesticides, etc. In terms of fluorine-containing liquid crystal chemicals, the company's main products are 3,5-difluorobromobenzene, 3,4,5-trifluorobromobenzene, 3,4,5-trifluorophenol, and 2,3,4-trifluoroaniline. Ranking first in the country; in terms of pharmaceutical and chemical industry, the company's main product 2,3,4-trifluoronitrobenzene ranks first in sales in the country; in terms of pesticide chemicals, the company's main products 3,5-difluoroaniline and 2,4-difluoro The sales volume of benzene ranks first in the country. 12. Photoresist: Electronic chemicals: Yongtai New Materials’ annual 1,500-ton CF photoresist project has entered the project acceptance stage. The company's annual production capacity of 60 tons of organic light-emitting diode electronic materials construction project is progressing steadily, and it continues to expand its layout in the field of flat panel displays.